tirzepatide articles 🧠 reduces food energy intake by impacting brain areas controlling ingestive behavior. This small Phase 1 RCT (n=114) explored how tirzepatide changes eating behavior—and the brain's response to food—in people with Frontiers | GLP-1/GIP dual agonist

GLP-1Rs are expressed in the pancreas, intestinal intraepithelial lymphocytes, myocardium, adipose tissue, kidney, liver, blood vessels, lungs and in the CNS.2,3 Although GLP-1 is known for its incretin effect, which it shares with glucose-dependent insulinotropic peptide (GIP), the intake-regulating action, essential for its efficacy against obesity, occurs through its interaction with receptors located in the CNS.1,5 The GLP-1 peptide can reach the central nervous system (CNS) via peripheral vagal afferents, which transmit its action through the nodose ganglion to the nucleus tactus solitarius (NTS)

The American Diabetes Association's Diabetes Plate Method (filling half your plate with non-starchy vegetables, one-quarter with protein, and one-quarter with carbohydrates) provides a helpful visual guide for meal composition

Metabolic comorbidities and hypertension in psoriasis patients in France

They're okay with slower progress if it means they can function at work, avoid nausea, and feel like themselves while the weight comes off